![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRP1B |
Gene summary for LRP1B |
![]() |
Gene information | Species | Human | Gene symbol | LRP1B | Gene ID | 53353 |
Gene name | LDL receptor related protein 1B | |
Gene Alias | LRP-1B | |
Cytomap | 2q22.1-q22.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9NZR2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
53353 | LRP1B | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.24e-03 | 1.97e-01 | -0.1808 |
53353 | LRP1B | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.94e-02 | 2.72e-01 | -0.2196 |
53353 | LRP1B | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.47e-04 | 1.66e-01 | -0.059 |
53353 | LRP1B | HTA11_7663_2000001011 | Human | Colorectum | SER | 4.38e-02 | 2.49e-01 | 0.0131 |
53353 | LRP1B | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.68e-03 | 3.08e-01 | 0.0112 |
53353 | LRP1B | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.05e-02 | 1.71e-01 | 0.0588 |
53353 | LRP1B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.07e-05 | 2.74e-01 | 0.281 |
53353 | LRP1B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.19e-17 | 4.84e-01 | 0.3859 |
53353 | LRP1B | NAFLD1 | Human | Liver | NAFLD | 1.31e-03 | 6.31e-01 | -0.04 |
53353 | LRP1B | HCC1_Meng | Human | Liver | HCC | 2.06e-05 | -4.12e-02 | 0.0246 |
53353 | LRP1B | HCC2 | Human | Liver | HCC | 5.93e-03 | 1.50e+00 | 0.5341 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006898 | Colorectum | AD | receptor-mediated endocytosis | 76/3918 | 244/18723 | 1.07e-04 | 1.59e-03 | 76 |
GO:00068981 | Colorectum | MSS | receptor-mediated endocytosis | 69/3467 | 244/18723 | 1.18e-04 | 1.82e-03 | 69 |
GO:00068984 | Liver | NAFLD | receptor-mediated endocytosis | 49/1882 | 244/18723 | 1.80e-06 | 7.78e-05 | 49 |
GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRP1B | SNV | Missense_Mutation | rs267598906 | c.12301G>A | p.Asp4101Asn | p.D4101N | Q9NZR2 | protein_coding | tolerated(0.56) | benign(0.007) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
LRP1B | SNV | Missense_Mutation | novel | c.3106G>C | p.Asp1036His | p.D1036H | Q9NZR2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
LRP1B | SNV | Missense_Mutation | c.1555C>T | p.Pro519Ser | p.P519S | Q9NZR2 | protein_coding | tolerated(0.09) | probably_damaging(0.996) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
LRP1B | SNV | Missense_Mutation | c.4049N>C | p.Tyr1350Ser | p.Y1350S | Q9NZR2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
LRP1B | SNV | Missense_Mutation | novel | c.2155N>T | p.Ile719Phe | p.I719F | Q9NZR2 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRP1B | SNV | Missense_Mutation | rs201825848 | c.10414G>A | p.Asp3472Asn | p.D3472N | Q9NZR2 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
LRP1B | SNV | Missense_Mutation | rs142974716 | c.6778N>A | p.Asp2260Asn | p.D2260N | Q9NZR2 | protein_coding | tolerated(0.21) | benign(0.021) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
LRP1B | SNV | Missense_Mutation | c.12103N>G | p.Asn4035Asp | p.N4035D | Q9NZR2 | protein_coding | tolerated(1) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRP1B | SNV | Missense_Mutation | c.10698N>G | p.Ile3566Met | p.I3566M | Q9NZR2 | protein_coding | deleterious(0) | benign(0.394) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRP1B | SNV | Missense_Mutation | rs762967476 | c.12705N>C | p.Leu4235Phe | p.L4235F | Q9NZR2 | protein_coding | tolerated(0.35) | benign(0.02) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
53353 | LRP1B | CLINICALLY ACTIONABLE, DRUG RESISTANCE | DOXORUBICIN | DOXORUBICIN | 22896685 |
Page: 1 |